SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates. "Sagimet is committed to bringing innovative therapies to MASH patients, following the successful results of our Phase 2b FASCINATE-2 clinical trial of denifanstat in MASH F2-F3 patients, particularly in more advanced F3 stage patients. In a Phase 1 clinical trial in patients with and without hepatic impairment, denifanstat exhibited similar pharmacokinetic cha

SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of denifanstat in MASH will be presented at the European Association for the Study of Liver (EASL) Congress 2025 being held May 7-10, 2025 in Amsterdam, Netherlands. EASL Presentation Details: Title:Assessment of the metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to d

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the clearance of its Investigational New Drug (IND) application for TVB-3567, the Company's second fatty acid synthase (FASN) inhibitor. TVB-3567 is a potent and selective small molecule FASN inhibitor, planned to enter clinical development for the treatment of acne. The IND with the U.S. Food and Drug Administration's

SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation on denifanstat's effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium being held February 23-26, 2025 in Banff, Canada. The presentation will feature lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial of denifanstat in MASH. MASH Pathogenesis and Therapeutic Approaches Keystone Symp

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2/F3 MASH. MASH-TAG 2025 Presentation Details: Title:FASN InhibitorsPresen

SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York. A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developin

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (

Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology Successful completion of end-of-Phase 2 interactions with FDA on the development of denifanstat for MASH; Phase 3 program initiation expected by end of 2024 Anticipated cash runway through 2025, with cash, cash equivalents and marketable securities totaling $170.0 million as of September 30, 2024 SAN MATEO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic p

-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024. This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40 once-daily oral tablet for the treatment of moderate to severe acne vulgaris. 480 patie

SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 5 p.m. PST in Rancho Palos Verdes, California. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutica

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00

UBS initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $12.00

Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously

H.C. Wainwright initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $32.00

Leerink Partners initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $26.00

TD Cowen initiated coverage of Sagimet Biosciences with a rating of Outperform

Piper Sandler initiated coverage of Sagimet Biosciences with a rating of Overweight and set a new price target of $67.00

Goldman initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $33.00

JMP Securities initiated coverage of Sagimet Biosciences with a rating of Mkt Outperform and set a new price target of $30.00

8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)

8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

DEF 14A - Sagimet Biosciences Inc. (0001400118) (Filer)

S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

10-K - Sagimet Biosciences Inc. (0001400118) (Filer)

8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

3 - Sagimet Biosciences Inc. (0001400118) (Issuer)

3 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

4 - Sagimet Biosciences Inc. (0001400118) (Issuer)